RegeneRx partner signs LOI with global ophthalmology CRO for Phase 3 clinical trials in neurotrophic keratitisJuly 19th 2022
The company and its U.S. joint venture partner and licensee, HLB Therapeutics, signed a letter of intent this week with a global ophthalmology contract research organization to conduct a pair of phase 3 clinical trials simultaneously beginning in the fall in the U.S. and Europe for patients with neurotrophic keratitis.
Study: Assaults with paintball guns cause more serious eye injuries than previously knownJuly 19th 2022
University of Chicago Medical Center investigators reviewed 2 years of data on assaults with paintball guns found more patients than expected suffered vision-threatening emergencies after being struck in the eye, with several experiencing a rupture of the eyeball or even permanent blindness.
American Academy of Pediatrics joins ophthalmology organizations to offer guidance to pediatricians on vision disorders following concussionJuly 18th 2022
Children may find it difficult to return to play or school after a concussion, and ophthalmologists and pediatricians can help identify if some will need special learning accommodations or additional referral for treatment.
Two-year data confirms faricimab improves vision for patients diagnosed with wet-AMDJuly 14th 2022
In the TENAYA and LUCERNE studies, more than 60% of faricimab patients could be treated every 4 months at 2 years, an increase from 45% at year 1. Study results are being presented at the American Society of Retina Specialists 2022 annual meeting in New York.
Research to Prevent Blindness awards grant to OU Department of OphthalmologyJuly 12th 2022
The University of Oklahoma Health Sciences Center has received an unrestricted grant from Research to Prevent Blindness for $575,000 over 5 years to support eye research conducted by the Department of Ophthalmology.
Wills Eye Hospital names new co-chief residentsJuly 12th 2022
Charles Brodowski, MD, and Patrick Rapuano, MD, have been named co-chief residents at Wills Eye Hospital, and will lead the team of resident doctors on staff, focusing on training and recruitment while attending to their own medical resident duties.
Kala Pharmaceuticals completes sale of Eysuvis, Inveltys to Alcon Inc.July 11th 2022
Kala Pharmaceuticals Inc. announced that it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was first announced in May.
When it comes to ADHD and ASD, the eyes could reveal allJune 26th 2022
Investigators have found that recordings from the retina could identify distinct signals for both attention deficit hyperactivity disorder and autism spectrum disorder, providing a potential biomarker for each condition.
RegeneRx licensee to expand Phase 3 clinical trial program with RGN-259June 24th 2022
RegeneRx Biopharmaceuticals Inc. said its U.S. joint venture partner and licensee, HLB Therapeutics, will expand its ophthalmic clinical development program with RGN-259 in two indications, neurotrophic keratopathy and dry eye disease.
LIGHTSITE III trial data demonstrates improvement in vision in intermediate dry AMDJune 23rd 2022
LumiThera Inc. noted that the trial results demonstrated statistically significant improvement in the prespecified primary endpoint in BCVA at 13 months in the PBM treatment group over the sham-treatment group.
How quality vision builds a foundation for safety and everyday activitiesJune 22nd 2022
As ophthalmologists observe Cataract Awareness Month this June, William L. Soscia, MD, medical director at Center for Sight, in Sarasota, Florida, focuses on the importance of having excellent vision for safety and everyday functions.
Bausch + Lomb receives permanent J-Code for triamcinolone acetonide injectable suspensionJune 21st 2022
The U.S. Centers for Medicare and Medicaid Services code is effective July 1 and will enhance access to Xipere, the only therapy available in the United States for suprachoroidal use in the treatment of macular edema associated with uveitis.
Foundation Fighting Blindness announces leadership changesJune 21st 2022
Jason Menzo is named CEO, while Russell Kelley, PhD, MBA, will become managing director of the RD Fund. Ben Yerxa, PhD, will take the helm of Opus Genetics, the first RD Fund- and foundation-backed spin-off company.